Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155203 · ClinicalTrials.gov registry record · Phase 3
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions
A Phase 3 study of Secondarily Infected Traumatic Skin Lesions, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 657
- Enrollment target
- 1
- Study location
NCT04155203: Completed Phase 3 study of Secondarily Infected Traumatic Skin Lesions, sponsored by Padagis.
NCT04155203 is a Phase 3 study of Secondarily Infected Traumatic Skin Lesions that has completed, run by Padagis. The registered enrollment target is 657 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04155203, a Phase 3 study of Secondarily Infected Traumatic Skin Lesions, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 657 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the safety and efficacy of Perrigo's product to an FDA approved product, and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG Mupirocin Calcium
Study Locations (1)
Florida
- Palm Beach Research Center - West Palm Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 657 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2021-06-01 |
| Phase | Phase 3 |
What the finished NCT04155203 record still lists
NCT04155203 is an interventional study that assigns participants to a tested intervention. The registered 657 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Secondarily Infected Traumatic Skin Lesions appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT04155203 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04155203 about?
NCT04155203 is a clinical study titled "To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions". To compare the safety and efficacy of Perrigo's product to an FDA approved product, and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions
What is the current status of trial NCT04155203?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 657 participants. The study started on 2019-10-15. Estimated completion is 2021-06-01.
What conditions does trial NCT04155203 study?
This clinical trial studies the following conditions: Secondarily Infected Traumatic Skin Lesions.
What interventions are being tested in trial NCT04155203?
The interventions under investigation include: Vehicle (DRUG), Mupirocin Calcium (DRUG).
Who is sponsoring clinical trial NCT04155203?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04155203 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04155203's enrollment target sits among peer trials
657 564th of 2000 higher than 1,436 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- NCT05338697 · 657 participants
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
- NCT05407129 · 656 participants · NA
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
- NCT06127199 · 656 participants · NA
Contraceptive Efficacy Study of Ovaprene
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI